Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opioid Induced Gait Variability in Knee Osteoarthritis
NCT03121547Phase 2Completed
- Sponsor
- Frederiksberg Hospital
- Start
- May 2015
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tapentadol and tramadol in knee osteoarthritis (OA) and pain, sponsored by Frederiksberg Hospital. Primary endpoint: Changes in Gait variability at 6 hours. Started May 2015; status: completed.
02
Drugs
tapentadoltramadol
03
Conditions
knee osteoarthritis (OA)pain
Beyond the preview
Go deeper on NCT03121547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03121547.